ReviewInflammatory intestinal diseases2016
New and Evolving Immunotherapy in Inflammatory Bowel Disease.
Review in Inflammatory intestinal diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Chitosan nanoparticles of rutin mitigated histological changes induced in DNCB-induced colitis by enhanced modulation of inflammation and oxidative stress.Journal of molecular histology · 2025Article
- Mapping the Evolution of IBD Treatment: A Bibliometric Study on Biologics and Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Review
- An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations inACS biomaterials science & engineering · 2023Article
- Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy.Biomedicines · 2023Review
- Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Biomedicines · 2022Review
- Targeted therapy of irritable bowel syndrome with anti-inflammatory cytokines.Clinical journal of gastroenterology · 2022Review
- The effect of a fennel seed extract on the STAT signaling and intestinal barrier function.PloS one · 2022Article
- Biological drug and drug delivery-mediated immunotherapy.Acta pharmaceutica Sinica. B · 2021Review
- ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Emerging roles of metabolites of ω3 and ω6 essential fatty acids in the control of intestinal inflammation.International immunology · 2019Review
- Protective effect of galangin against dextran sulfate sodium (DSS)-induced ulcerative colitis in Balb/c mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.World journal of gastroenterology · 2018Article
- Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results.BioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCrohn's disease and ulcerative colitis are chronic inflammatory disorders associated with a dysregulated adaptive and innate immune response to gut commensals in genetically susceptible individuals. The pathogenesis of inflammatory bowel disease is complex, and the disease is characterized by significant phenotypic and genotypic heterogeneity. SUMMARY: The introduction of anti-TNF biologics has resulted in improved clinical outcomes in patients with severe and moderately severe disease, but the current treatment paradigm continues to depend on systemic immunosuppression (steroids and immunomodulators) and surgical intervention in a significant number of patients, underscoring a significant unmet need. More recently, a number of genetic and immunologic abnormalities have been unraveled including aberrant intestinal mucosal defense function, abnormal intestinal permeability, dysregulated bacterial antigen processing by macrophages and presentation to T cells, cellular immune regulation and signaling, cytokine production, and leukocyte trafficking. KEY MESSAGES: Understanding these molecular mechanisms and effector pathways presents an opportunity for the development of new and improved targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.